非布司他治疗慢性肾脏病伴高尿酸血症的临床效果分析

目的对非布司他治疗慢性肾脏病伴高尿酸血症的临床效果进行研究.方法46例慢性肾脏病伴高尿酸血症患者,随机分为常规组与科研组,各23例.常规组采用别嘌醇片治疗,科研组采用非布司他治疗.比较两组治疗前后尿酸、血尿素氮、血肌酐水平及药物不良反应发生情况.结果治疗后,科研组血尿酸、血尿素氮及血肌酐水平分别为(290.92±59.12)μmmol/L、(13.06±5.23)mmol/L、(269.12±52.42)μmmol/L,低于常规组的(520.81±60.14)μmmol/L、(15.81±5.73)mmol/L、(293.34±56.18)μmmol/L,差异有统计学意义(P<0.05).科研组药物不良反应发生率4.35%低于常规组的43.48%,差异有统计学意义(P<0.05).结论慢性肾脏病伴高尿酸血症采用非布司他进行治疗,能够明显降低患者的尿酸、血尿素氮、血肌酐水平,不良反应少,安全性高,疗效确切.

Analysis of clinical effect of febuxostat in the treatment of chronic kidney disease complicated by hyperuricemia

Objective To study the clinical effect of febuxostat in the treatment of chronic kidney disease complicated by hyperuricemia.Methods A total of 46 cases of chronic kidney disease complicated by hyperuricemia were randomly divided into conventional group and research group,with 23 cases in each group.The conventional group was treated by allopurinol tablets,and the research group was treated by febuxostat.The levels of uric acid,blood urea nitrogen and blood creatinine before and after treatment and occurrence of adverse drug reactions were compared between the two groups.Results After treatment,the levels of uric acid,blood urea nitrogen and blood creatinine were(290.92±59.12)μmmol/L,(13.06±5.23)mmol/L and(269.12±52.42)μmmol/L in the research group,which were lower than(520.81±60.14)μmmol/L,(15.81±5.73)mmol/L and(293.34±56.18)μmmol/L in the conventional group,and their difference was statistically significant(P<0.05).The incidence of adverse drug reactions 4.35%in the research group was lower than 43.48%in conventional group,and the difference was statistically significant(P<0.05).Conclusion Febuxostat shows affirmative efficacy for the treatment of chronic kidney disease complicated by hyperuricemia,and it can significantly reduce the levels of uric acid,blood urea nitrogen and blood creatinine of patients with fewer adverse reactions and high safety.